• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

    1.600 +0.050 (+3.23%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,037,125
    Open 1.530
    Bid (Size) 1.570 (1,000)
    Ask (Size) 1.580 (100)
    Prev. Close 1.550
    Today's Range 1.530 - 1.600
    52wk Range 1.150 - 2.700
    Shares Outstanding 52,346,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
    Via Investor Brand Network
    Topics Intellectual Property
    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
    Via Investor Brand Network

    Performance

    YTD
    -14.4%
    -14.4%
    1 Month
    +14.3%
    +14.3%
    3 Month
    +12.7%
    +12.7%
    6 Month
    -1.8%
    -1.8%
    1 Year
    +11.1%
    +11.1%

    More News

    Read More
    News headline image
    Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    News headline image
    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Participate in Upcoming Investor Conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Participate in Upcoming Investor Conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
    From Cellares Corp
    Via Business Wire
    News headline image
    Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗
    Via Stocktwits
    News headline image
    NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    A Look at Autolus Therapeutics's Upcoming Earnings Report ↗
    Via Benzinga
    News headline image
    Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Autolus Therapeutics plc - American Depositary Shares publicly traded?
    Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.
    What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?
    Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?
    The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market
    What is the current price of Autolus Therapeutics plc - American Depositary Shares?
    The current price of Autolus Therapeutics plc - American Depositary Shares is 1.600
    When was Autolus Therapeutics plc - American Depositary Shares last traded?
    The last trade of Autolus Therapeutics plc - American Depositary Shares was at 04/22/26 04:00 PM ET
    What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?
    The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 83.75M
    How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?
    Autolus Therapeutics plc - American Depositary Shares has 84M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.